hexanucleotide repeat were found, suggesting that there is no causal relationship between C9orf72 and DLB. Conclusion: Our data illustrate that C9orf72 screening of clinically diagnosed DLB patients should only be considered in cases with a family history of motor neuron disease or frontotemporal dementia to distinguish between mimic diseases.
Introduction
Dementia with Lewy bodies (DLB) is a degenerative neurological disorder clinically characterized by a combination of progressive cognitive impairment, altered mental status, neuroleptic sensitivity, visual hallucinations and parkinsonism [1] . DLB is the second most prevalent neurodegenerative dementia in the elderly population after Alzheimer disease, accounting for approximately 20% of cases [2] . The molecular mechanism of DLB is largely unknown, although a genetic component has been proposed [3] .
Key Words
Dementia with Lewy bodies · Amyotrophic lateral sclerosis · Frontotemporal dementia · C9orf72 · Hexanucleotide repeat expansion Abstract Background: Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia affecting the elderly. The GGGGCC hexanucleotide expansion mutation at the C9orf72 locus has been identified as a major cause of amyotrophic lateral sclerosis and frontotemporal dementia, raising the question of whether this mutation is a factor in DLB. Furthermore, a small number of clinically diagnosed DLB patients have previously been reported to carry the pathologic C9orf72 hexanucleotide repeat expansion. Objective: To explore whether the C9orf72 mutation is present in pathologically confirmed DLB patients. Methods: We screened a cohort of 111 definite DLB cases with extensive Lewy body pathology for the C9orf72 hexanucleotide repeat expansion using the repeat-primed polymerase chain reaction assay. Results: No pathogenic expansions of the C9orf72 A [GGGGCC] n hexanucleotide expansion at the C9orf72 locus is the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia [4, 5] . This repeat expansion has also been identified in patients clinically diagnosed with Alzheimer disease, atypical parkinsonism or psychosis [6] [7] [8] . Psychosis is a common symptom in DLB, raising the question of whether the C9orf72 hexanucleotide expansion is a genetic factor in DLB. Previous clinical studies have considered this question [9] [10] [11] [12] , with one study reporting 2 out of 102 clinically diagnosed DLB patients as having a pathogenic repeat expansion [10] . However, the clinical diagnosis of DLB is challenging, with a high false-positive rate due to mimic syndromes [13, 14] . As a consequence, the research community is increasingly relying on specimens that are pathologically confirmed as this represents the gold standard for diagnosis. To investigate if C9orf72 repeat expansions have a role in pathologically confirmed DLB, we conducted a genetic screening study on a cohort of 111 definite DLB cases. The cohort included neocortical cases (n = 86) and transitional-type DLB cases (n = 25) diagnosed using the criteria of McKeith et al. [15] . All subjects were Caucasian, with males representing 67% of the cases. The average age of death was 78 years (range 57-94 years). The majority of patients (66%) also met the pathological criteria for Alzheimer disease. Additional clinicopathological characteristics are displayed in table 1 . DNA was extracted from frozen brain sections using the Qiagen DNeasy extraction protocol (Qiagen, Hilden, Germany). The hexanucleotide repeat at the C9orf72 locus was genotyped using the repeat-primed polymerase chain reaction (PCR) assay as previously described [4] . The resulting PCR amplicons were analyzed on an Applied Biosystems 3730xl DNA Analyzer (Life Technologies, Grand Island, N.Y., USA). A pathologic expansion was defined as >30 GGGGCC repeats [4] .
Results
We observed hexanucleotide repeats of <20 in our cohort, which is considered normal. None of the 111 pathologically confirmed cases carried a pathogenic C9orf72 repeat expansion.
Discussion
This study shows that the pathogenic C9orf72 expansion is not present in pathologically confirmed Caucasian DLB patients. In a large screening study of familial Alzheimer dementia cases, Harms et al. [16] identified an Alzheimer dementia patient with a pathological C9orf72 repeat expansion. Interestingly, this case was also found to have neocortical Lewy bodies in addition to typical Alzheimer pathology. However, tissue was not available for the evaluation of pathologic changes consistent with frontotemporal dementia. It is possible that the pathologic C9orf72 mutation in this patient was coincidental and that this case could have had frontotemporal dementia in addition to Alzheimer dementia. Cases of frontotemporal lobar degeneration with motor neuron disease can present with symptoms mimicking DLB [13] . Our data suggest that the presence of a pathologic C9orf72 hexanucleotide expansion in a clinically diagnosed DLB case likely represents an atypical presentation of fronto- 
